Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with chemotherapy or as single-agent treatment after failure of second-line or later therapy in advanced ovarian cancer
ChiCTR1800015202Phase 4Not yet recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Mar 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Yibin Second People's Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR1800015202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015202.